A comparative study of Hemoforce Family as a treatment for iron deficiency anaemia in Ghanaian patients.
- Conditions
- Haematological DisordersNutritional, Metabolic, EndocrineAnaemia
- Registration Number
- PACTR202209576526787
- Lead Sponsor
- Shalina Healthcare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Male or female (=12 years) suffering from iron deficiency anaemia having hemoglobin between 9 to 12 g/dl.
Patients or parents willing to provide written informed consent to use personal and/or health data prior to the entry into the study.
Anaemia not linked to iron deficiency.
Hemoglobin less than 9 g/dL.
Allergy to iron derivatives.
Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis, renal disease, autoimmune disease.
Those who had received parenteral iron treatment earlier within 3 months before the start of the study.
Patients with history of chronic blood loss.
Alcohol abuse within past 6 months.
Hemosiderosis, hemochromatosis or other iron storage disorders.
Patients with a history or present illness that is a malignant tumor or autoimmune disease.
Patients who underwent oral administration of an iron preparation (including an over-the-counter drug or supplement) within 4 weeks before the screening.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin measures at baseline, 3 weeks, and 8 weeks after treatment to determine efficacy
- Secondary Outcome Measures
Name Time Method Ferritin levels <br>Physician consultation and examination to determine General wellness (weight correction, weakness/lethargy) at baseline and 8 weeks<br>Physician consultation and examination to determine side effects (constipation, nausea, organoleptic and others)